Rein Therapeutics
RNTX
60 hedge funds and large institutions have $42.5M invested in Rein Therapeutics in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 3 reducing their positions, and 6 closing their positions.
533% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 3
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
186% more capital invested
Capital invested by funds: $14.8M → $42.5M (+$27.6M)
30% more funds holding
Funds holding: 46 → 60 (+14)
7.1% more ownership
Funds ownership: 40.65% → 47.75% (+7.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCC
Cable Car Capital
San Francisco,
California
|
+$5.78M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$5.45M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.57M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.12M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$41.2K |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$26K |
| 3 |
HF
HRT Financial
New York
|
-$20K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$13K |
| 5 |
GS
Gagnon Securities
New York
|
-$12.6K |
RNTX Hedge Fund Activity: Q2 2026 in Review
60 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2026, worth a combined $42.5M — up 186% from $14.8M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RNTX positions and 6 closed out — a net gain of 15 holders — while 19 added to existing stakes and 3 trimmed.
The largest buyer was Cable Car Capital, adding an estimated $5.78M. The largest seller was Two Sigma Securities, exiting entirely with an estimated $41.2K sold.
- 60 institutional investors held Rein Therapeutics (RNTX) as of Q2 2026, up from 46 in Q1 2026.
- Funds reported $42.5M of Rein Therapeutics stock for Q2 2026, up 186% quarter-over-quarter.
- 21 funds opened new Rein Therapeutics positions in Q2 2026 and 6 closed out, a net change of +15 holders.
- The largest Rein Therapeutics buyer in Q2 2026 was Cable Car Capital, an estimated $5.78M added.
- The largest Rein Therapeutics seller in Q2 2026 was Two Sigma Securities, an estimated $41.2K sold.
Based on aggregated 13F filings for Q2 2026.